Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Clinical trial NCT04578756 · COMPLETED

Trial details

NCT number: NCT04578756
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Schizophrenia Bipolar I Disorder Autism Spectrum Disorder (ASD)

Start date: 2021-02-01
Primary completion: 2025-10-06
Enrollment: 310

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.